Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 17/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7976 | 1.00 | EGLN1 (0.63) | EGLN1RAB9ANPC1ALDH1A1TP53 | |
| SCHEMBL7718 | 0.90 | EGLN1 (0.55) | EGLN1RAB9ANPC1ALDH1A1TP53 | |
| SCHEMBL7717 | 0.90 | EGLN1 (0.55) | EGLN1RAB9ANPC1ALDH1A1TP53 | |
| SCHEMBL7956 | 0.88 | EGLN1 (0.54) | EGLN1RAB9ANPC1ALDH1A1TP53 | |
| SCHEMBL8497 | 0.79 | EGLN1 (0.66) | EGLN1 | |
| SCHEMBL17107185 | 0.69 | RAB9A (1.00) | RAB9ANPC1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL17107186 | 0.69 | RAB9A (1.00) | RAB9ANPC1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL17132006 | 0.69 | RAB9A (1.00) | RAB9ANPC1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL17132003 | 0.67 | RAB9A (0.71) | RAB9ANPC1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL17107128 | 0.67 | RAB9A (0.71) | RAB9ANPC1ALDH1A1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | UNIVERSITÀ DI PISA (IT) | 2012-12-06 | — | — | US | disclosed |
| EP-2499114-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Universita Di Pisa (IT) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011054525-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | UNIVERSITA' DI PISA (IT) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LDHA, LDHB, DLD | EGLN1 159/4885RAB9A 2969/4885NPC1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.